MedTrace Logo

Nimotuzumab in Adults With Pancreatic Cancer

NCT00561990 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 188

Last updated 2015-10-15

No results posted yet for this study

Summary

CHEMOTHERAPY-NAIVE PATIENTS WITH LOCALLY ADVANCED OR METASTATIC PANCREATIC CANCER

Conditions

  • Pancreatic Cancer, Advanced or Metastatic

Interventions

DRUG

Nimotuzumab

Sponsors & Collaborators

  • Marienhospital Herne

    collaborator OTHER

  • University of Kiel

    collaborator OTHER

  • Gemeinschaftspraxis für Hämatologie und Onkologie, Köln, Germany

    collaborator UNKNOWN

  • Onkologisches Zentrum III, Medizinische Klinik, Mannheim, Germany

    collaborator UNKNOWN

  • Onkologische Gemeinschaftspraxis, Mülheim, Germany

    collaborator UNKNOWN

  • II. Medizinische Klinik u. Poliklinik, Klinikum rechts der Isar, München, Germany

    collaborator UNKNOWN

  • Hämatologisch-Onkologische Schwerpunktpraxis, Münster, Germany

    collaborator UNKNOWN

  • Praxis für Internistische Onkologie und Hämatologie, Recklinghausen, Germany

    collaborator UNKNOWN

  • Oncoscience AG

    lead INDUSTRY

Principal Investigators

  • Dirk Strumberg, MD · University Bochum

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-09-30
Primary Completion
2013-01-31
Completion
2014-01-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00561990 on ClinicalTrials.gov